Cassava Sciences Inc vs Gogoro Inc — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while Gogoro Inc trades at $2.51 (market cap $52.19M). The key difference: Cassava Sciences Inc and Gogoro Inc are close in size by market cap. Which is the better fit depends on your goals.
| FLNA | GGR | |
|---|---|---|
Market Cap | $47.75M | $52.19M |
Sector | Health | Technology |
52-Week High | $4.64 | $7.50 |
52-Week Low | $0.87 | $2.55 |
Enterprise Value | -$34.93M | $354.63M |
Signals from Pluang's Aura AI — not financial advice
FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.
The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.
GGR trades at $2.46, down 4.65% today, with a bearish technical signal despite oversold RSI readings. The company reported Q1 2026 revenue of $281.48M with negative net income of -$79.97M, though operating cash flow improved to $35.90M. Valuation metrics show low P/S (0.14) and P/B (0.45) ratios, but profitability remains weak with negative ROE (-50.38%) and net margins (-24.68%).
The outlook remains challenging with persistent losses and negative cash flow, though management highlights margin improvements and subscriber growth. Key risks include execution on profitability and competitive pressures. Analyst consensus is neutral (100% Hold), reflecting cautious sentiment amid ongoing turnaround efforts.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →